Hepatobiliary Manifestations in UC Patients

This is a prospective observational study on 167 patients with hepatobiliary manifestations who underwent two-stage elective LRP with IPAA for UC from June 2013 to June 2018 at our universities’ hospitals. Inclusion criteria were all patients between 18 and 69 years; men and women with at least one hepatobiliary manifestation. In patients with UC, surgery was decided according to The European Crohn’s and Colitis Organisation guidelines on therapeutics in UC[11 (link)]. Exclusion criteria included: Alcohol abuse, severe heart failure or type II diabetes mellitus, complications or death related to LRP operation, liver toxicity of IBD-related medications, active or chronic viral hepatitis, hemochromatosis, Wilson's disease, drugs-induced steatosis (amiodarone or tamoxifen), morbid obesity or patients undergoing bariatric surgery, immunoglobulin G4-related cholangitis; human immunodeficiency virus/acquired immune deficiency syndrome; tuberculosis; secondary sclerosing cholangitis; cholangiocarcinoma; complications of advanced PSC (hepatic encephalopathy, portal hypertension, hepatorenal syndrome, or hepato-pulmonary syndrome; end-stage liver failure), hypercoagulability status (systemic lupus erythematosus, increased von Willebrand factor or increased homocysteine level), oral contraceptive pills, Grave's disease, dyslipidemia, and previous biliary tract surgery including cholecystectomy.

Partial Protocol Preview
This section provides a glimpse into the protocol.
The remaining content is hidden due to licensing restrictions, but the full text is available at the following link: Access Free Full Text.

Habeeb T.A., Hussain A., Podda M., Cianci P., Ramshaw B., Safwat K., Amr W.M., Wasefy T., Fiad A.A., Mansour M.I., Moursi A.M., Osman G., Qasem A., Fawzy M., Alsaad M.I., Kalmoush A.E., Nassar M.S., Mustafa F.M., Badawy M.H., Hamdy A., Elbelkasi H., Mousa B., Metwalli A.E., Mawla W.A., Elaidy M.M., Baghdadi M.A, & Raafat A. (2023). Hepatobiliary manifestations following two-stages elective laparoscopic restorative proctocolectomy for patients with ulcerative colitis: A prospective observational study. World Journal of Gastrointestinal Surgery, 15(2), 234-248.

Publication 2023

A 167 Acquired immune deficiency syndrome Alcohol abuse Amiodarone Bariatric surgery Biliary tract surgery Cholangiocarcinoma Cholangitis Cholecystectomy Chronic hepatitis Colitis Crohn s Drugs Dyslipidemia End liver failure European Grave disease Heart failure Hemochromatosis Hepatic encephalopathy Hepato pulmonary syndrome Hepatorenal syndrome Homocysteine Human immunodeficiency virus Hypercoagulability Immunoglobulin g4 Liver Medications toxicity Morbid obesity Oral contraceptive pills Patients Portal hypertension Steatosis Systemic lupus erythematosus Tamoxifen Therapeutics Tuberculosis Type ii diabetes mellitus Von willebrand factor Wilson disease Women

Corresponding Organization :

Other organizations : Zagazig University, Homerton University Hospital, University of Cagliari, University of Foggia, Suez University, Sohag University, Al-Azhar University, National Water Research Center

Top 5 similar protocols

Variable analysis

independent variables

None explicitly mentioned

dependent variables

Hepatobiliary manifestations in patients with ulcerative colitis (UC)
Outcomes of two-stage elective laparoscopic restorative proctocolectomy (LRP) with ileal pouch-anal anastomosis (IPAA) for UC

control variables

Patients between 18 and 69 years of age
Patients with at least one hepatobiliary manifestation
Patients with UC where surgery was decided according to The European Crohn's and Colitis Organisation guidelines on therapeutics in UC
Exclusion of patients with alcohol abuse, severe heart failure or type II diabetes mellitus, complications or death related to LRP operation, liver toxicity of IBD-related medications, active or chronic viral hepatitis, hemochromatosis, Wilson's disease, drugs-induced steatosis (amiodarone or tamoxifen), morbid obesity or patients undergoing bariatric surgery, immunoglobulin G4-related cholangitis, human immunodeficiency virus/acquired immune deficiency syndrome, tuberculosis, secondary sclerosing cholangitis, cholangiocarcinoma, complications of advanced PSC, hypercoagulability status, oral contraceptive pills, Grave's disease, dyslipidemia, and previous biliary tract surgery including cholecystectomy

controls

Positive control: Not explicitly mentioned
Negative control: Not explicitly mentioned

Annotations

Based on most similar protocols

Etiam vel ipsum. Morbi facilisis vestibulum nisl. Praesent cursus laoreet felis. Integer adipiscing pretium orci. Nulla facilisi. Quisque posuere bibendum purus. Nulla quam mauris, cursus eget, convallis ac, molestie non, enim. Aliquam congue. Quisque sagittis nonummy sapien. Proin molestie sem vitae urna. Maecenas lorem.

As authors may omit details in methods from publication, our AI will look for missing critical information across the 5 most similar protocols.

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!